ER-100 is a gene therapy using three Yamanaka factors, delivered to the eye. In 2024, Life Biosciences reported improved retinal and optic nerve function in monkeys after optic nerve stroke. Now the first human results are in. Three people with glaucoma received a low dose. Two months later, none had experienced a serious side effect, and two scored better on vision tests than at the start. 🔗 Watch the full video: https://youtu.be/LH_GcDMLF0U